Human anti gp41, Clone AbD08066 specifically recognizes the Human Immunodeficiencey Virus (HIV) envelope glycoprotein 41 (gp41).
The fusion of the HIV-1 with the membrane of the host cell is the first step in the process of viral infection and replication and involves confomational changes in the gp120 and gp41 viral envelope proteins. It is now known that the HIV envelope glycoprotein gp41 contains a highly conserved N-heptad repeat (N-HR) region which is conserved in many HIV-1 strains and as such it is hypothesized that this maybe a target for developing a vaccine (Gustchina et al. 2010).
Clone AbD8066 is a unique antibody that has been shown to be broadly neutralizing across a wide range of primary isolates from HIV-1 subtypes B and C (Gustchina et al. 2010).
A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a myc-tag (EQKLISEEDL) and a his-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
Metal chelate affinity chromatography
Recombinant protein corresponding to a conserved internal trimeric coiled-coil of the N-heptad repeat (N-HR) of HIV-1 gp41.
Approx. Protein Concentrations
Total protein concentration 0.5 mg/ml
Reagents In The Kit
Preparing The Antibody
Phosphate buffered saline
Store at -20oC only. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
12 months from date of despatch
Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.
For in vitro research purposes only, unless otherwise specified in writing by Bio-Rad.
For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
This antibody demonstrates neutralizing properties
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
1. Gustchina, E. et al. (2010) Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.PLoS Pathog. 6: e1001182.
2. Gustchina, E. et al. (2009) Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.Virology. 393: 112-9.
3. Gustchina, E et al. (2013) Complexes of Neutralizing and Non-Neutralizing Affinity Matured Fabs with a Mimetic of the Internal Trimeric Coiled-Coil of HIV-1 gp41.PLoS One. 8: e78187